LONDON (Reuters Health) – Data measuring the attractiveness of the UK as a location for pharmaceutical companies is to be published in the near future, the Department of Health said on Wednesday.
The move was announced after the first meeting of the Ministerial Industry Strategy Group, a new high-level group co-chaired by Health Minister Lord Philip Hunt and AstraZeneca chief executive Tom McKillop.
The group was set up to discuss strategic issues affecting the UK industry and to carry forward the recommendations of the joint government-industry Pharmaceutical Industry Competitiveness Task Force which was set up in 1999 after firms warned Tony Blair that action was required to ensure Britain kept its competitive edge.
In a news release, the Health Department said issues discussed by the group on Wednesday included the "development of competitiveness and performance indicators, which will set out comparative data on the attractiveness of the UK as a location for research-based pharmaceutical companies".
Other issues raised included the recent World Trade Organisation talks on access to medicines in developing countries and the proposed reform of the EU medicines licensing system.
However the department's statement made no reference to the National Institute for Clinical Excellence (NICE), fuelling industry concern that its call for a fundamental review of the controversial new cost effectiveness watchdog has been ignored.
The use of 46 competitiveness indicators was recommended by the task force in March to show whether the UK competitive environment is improving or worsening relative to its main competitor countries.
On the supply side, the indicators include the number of new graduates with relevant science degrees, venture capital invested in the pharmaceutical/biotech industry, government R&D spending, and the number of scientific research publications.
On the demand side, they include the system used to control drug prices or company profits and sales uptake of major new reimbursed products.
Other indicators will measure industry innovation, including the proportion of world first patents and the proportion of world pharmaceutical R&D spending.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!